Tag: M.W:600-700

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.51094-17-8,4,4′,4”,4”’-(21H,23H-porphine-5,10,15,20-tetrayl)tetrakis-Phenol,as a common compound, the synthetic route is as follows.,51094-17-8

COMPOUND 1; 5,10,15,20-tetralds-[4-(3-Trimeth34ammonio-propyloxy)-phenyl]- porphyrin tetrachloride; To a vigorously-stirred suspension of 5,10,15,20-tetrakis-(4-hydroxy- phenyl)-porphyrin (50 mg, 0.07 mmol) and K2CO3 (230 mg, 1.7 mmol) in DMF (20 mL), a solution of (l-bromopropyl)-trimethylammonium bromide (0.27 g, 1.05 mmol) in DMF (5 mL) is added dropwise at 5O0C during 30 mins. The mixture is stirred at 5O0C for 15 h. After removal of DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing with methanol (1 L), the pad is eluted with acetic acid. After evaporation of solvent from the eluate, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH20 eluting with n- butanol: water: acetic acid (4:5:1, by vol., upper phase). The recovered material is dissolved in the minimum volume of methanol and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 40O5 chloride form). The recovered tetrachloride salt is dried under high vacuum and obtained as a violet solid. 1H-NMR: deltaH (300MHz, CD3OD): 2.35-2.50 (bs. 8 H), 3.25-3.35 (bs, 36 H), 3.65- 3.75 (bs, 8 H), 4.35 (m, 8 H), 7.30, 8.10 (2 x d, 3J 8.5 Hz, 16 H), 8.80- 9.00 (bs, 8 H).

51094-17-8 4,4′,4”,4”’-(21H,23H-porphine-5,10,15,20-tetrayl)tetrakis-Phenol 135438030, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DESTINY PHARMA LIMITED; WO2006/765; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.54761-04-5,Ytterbium(III) trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.

Under the protection of nitrogen atmosphere, the amount of organic solvent (for the volume ratio of 1: 0.2 of a mixture of polyethylene glycol and 15-crown-5) was added 100 mmol of the compound of formula (I) 250 mmol of the compound of formula (II) above, 9 mmol of catalyst (3 mmol Pd(dba)2) With 6mmol A mixture of ytterbium trifluoromethanesulfonate ,12 mmol oxidizer silver acetate and 30 mmol accelerator N-n-butyl-N-methylpiperidine bis(trifluoromethanesulfonyl)imide salt, and then the temperature was raised to 70 C, and the reaction was stirred at that temperature for 6 hours. After the reaction is complete, the filtrate is adjusted to adjust the pH of the filtrate to neutral and then saturated with hydrogen carbonate Sodium aqueous solution is fully shaken washing, adding dichloromethane extraction, separation of organic phase, and then Dried over anhydrous sodium sulfate, concentrated under reduced pressure, the residue over 200-300 mesh silica gel column chromatography, in vivo A mixture of petroleum ether and acetone having a ratio of 1: 3 was used as the eluent to give a compound of formula (III) And the yield was 93.9%., 54761-04-5

The synthetic route of 54761-04-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Henan Academy Of Sciences Chemical Institute Co., Ltd.; Huo Cuimeng; Fu Yang; Chen Jin; Zhang Xin; Zhao Yongde; (9 pag.)CN105037081; (2016); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

54761-04-5, Ytterbium(III) trifluoromethanesulfonate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

54761-04-5, General procedure: ReBr(CO)3(N,N’-Phd-O,O’)Ln(OTf)3(THF) (III Y, Ln = Y; III Eu, Ln = Eu; III Yb, Ln = Yb) heterobimetallic complexes were synthesised by allowing 1.0 mmol (0.560 g) of fac-ReBr(CO)3(Phd) to react with 1.0 mmol of the respective anhydrous triflate salt Ln(OTf)3 in 20 mL of THF. After 72 h of stirring at ambient temperature, the solvent was evaporated under reduced pressure and diethyl ether (10 mL) was added. The solid thus separated was filtered, washed with a small amount of diethyl ether and dried.

The synthetic route of 54761-04-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Bortoluzzi, Marco; Battistel, Dario; Albertin, Gabriele; Daniele, Salvatore; Enrichi, Francesco; Rumonato, Riccardo; Chemical Papers; vol. 70; 1; (2016); p. 43 – 52;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

54761-04-5, Ytterbium(III) trifluoromethanesulfonate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,54761-04-5

General procedure: Compounds Ir6Ln (Ln=Eu, Tb, Er, Yb) were synthesized under similar optimized experimental conditions. A typical procedure for the preparation of [EuIr6(ppy)12(bpp)2(bppH)4](CF3SO3)¡¤18H2O (Ir6Eu) is described as below. Eu(CF3SO3)3 (0.0120g, 0.02mmol) was added to a methanol solution (5cm3) of [Ir(ppy)2(bppH)] (0.0135g, 0.02mmol). After heating the yellow solution at 100C under microwave irradiation for 30min, the filtrate was left to stand for one week at room temperature. Yellow block crystals were collected by suction filtration, washed with a minimum amount of methanol.

54761-04-5 Ytterbium(III) trifluoromethanesulfonate 2733225, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Zeng, Dai; Fan, Kun; Wang, Lu-Ping; Bao, Song-Song; Ren, Min; Zheng, Li-Min; Journal of Magnetism and Magnetic Materials; vol. 484; (2019); p. 139 – 145;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI